204 related articles for article (PubMed ID: 19723467)
1. New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab.
Silverman SL
Curr Osteoporos Rep; 2009 Sep; 7(3):91-5. PubMed ID: 19723467
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
3. Data from extension trials: denosumab and zoledronic acid.
Dore RK
Curr Osteoporos Rep; 2012 Mar; 10(1):16-21. PubMed ID: 22086442
[TBL] [Abstract][Full Text] [Related]
4. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of denosumab for treatment of bone loss in men and women.
Adler RA; Gill RS
Clin Interv Aging; 2011; 6():119-24. PubMed ID: 21753866
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
7. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
8. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
9. Developments in the pharmacotherapeutic management of osteoporosis.
Close P; Neuprez A; Reginster JY
Expert Opin Pharmacother; 2006 Aug; 7(12):1603-15. PubMed ID: 16872263
[TBL] [Abstract][Full Text] [Related]
10. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis].
Varenna M; Gatti D
Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563
[TBL] [Abstract][Full Text] [Related]
11. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Eriksen EF; Lyles KW; Colón-Emeric CS; Pieper CF; Magaziner JS; Adachi JD; Hyldstrup L; Recknor C; Nordsletten L; Lavecchia C; Hu H; Boonen S; Mesenbrink P
J Bone Miner Res; 2009 Jul; 24(7):1308-13. PubMed ID: 19257818
[TBL] [Abstract][Full Text] [Related]
12. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
13. [Denosumab--a new efficient osteoporosis therapy].
Rejnmark L; Vestergaard P; Mosekilde L
Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
[TBL] [Abstract][Full Text] [Related]
14. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
15. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
17. [Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].
Leszczyński P
Chir Narzadow Ruchu Ortop Pol; 2010; 75(3):168-71. PubMed ID: 21038635
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis: how long should we treat?
Sebba A
Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):502-7. PubMed ID: 18971678
[TBL] [Abstract][Full Text] [Related]
19. Osteoporosis: non-hormonal treatment.
Rizzoli R
Climacteric; 2007 Oct; 10 Suppl 2():74-8. PubMed ID: 17882678
[TBL] [Abstract][Full Text] [Related]
20. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Lambrinoudaki I; Vlachou S; Galapi F; Papadimitriou D; Papadias K
Clin Interv Aging; 2008; 3(3):445-51. PubMed ID: 18982915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]